Beta-blockers have similar pharmacologic effects but vastly different pharmacokinetic properties that influence their clinical usefulness across various disorders.
Pharmacokinetic differences may guide beta-blocker selection by disorder; leaves open head-to-head trials to confirm clinical impact.
Although all beta-blocking agents have similar pharmacologic effects, they have vastly different pharmacokinetic properties, which can influence the clinical usefulness of a given beta blocker in an individual patient. The efficacy of these drugs in a host of disorders-both cardiovascular and noncardiovascular-and their modes of action in these clinical contexts are examined and discussed.
No takes yet. Share an insight, caveat, or question.
William H. Frishman (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: